Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Nunn AJ, Meredith SK, Bayissa A, Bhatnagar AK, Chiang CY, Conradie F, Gopalan N, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Teferi M, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators. Goodall RL, et al. Among authors: torrea g. Lancet Respir Med. 2024 Dec;12(12):975-987. doi: 10.1016/S2213-2600(24)00186-3. Epub 2024 Oct 1. Lancet Respir Med. 2024. PMID: 39366400 Free article. Clinical Trial.
Strain diversity and gene mutations associated with presumptive multidrug-resistant Mycobacterium tuberculosis complex isolates in Northwest Ethiopia.
Ejo M, Torrea G, Diro E, Abebe A, Kassa M, Girma Y, Tesfa E, Ejigu K, Uwizeye C, Gehre F, de Jong BC, Rigouts L. Ejo M, et al. Among authors: torrea g. J Glob Antimicrob Resist. 2023 Mar;32:167-175. doi: 10.1016/j.jgar.2022.11.012. Epub 2022 Dec 5. J Glob Antimicrob Resist. 2023. PMID: 36470362 Free article.
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang CY, Conradie F, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Narendran G, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators. Goodall RL, et al. Among authors: torrea g. Lancet. 2022 Nov 26;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5. Epub 2022 Nov 8. Lancet. 2022. PMID: 36368336 Free PMC article. Clinical Trial.
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.
Kokebu DM, Ahmed S, Moodliar R, Chiang CY, Torrea G, Van Deun A, Goodall RL, Rusen ID, Meredith SK, Nunn AJ. Kokebu DM, et al. Among authors: torrea g. Int J Tuberc Lung Dis. 2022 Aug 1;26(8):753-759. doi: 10.5588/ijtld.22.0073. Int J Tuberc Lung Dis. 2022. PMID: 35898125 Free PMC article.
Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings.
Van Deun A, Bola V, Lebeke R, Kaswa M, Hossain MA, Gumusboga M, Torrea G, De Jong BC, Rigouts L, Decroo T. Van Deun A, et al. Among authors: torrea g. JAC Antimicrob Resist. 2022 Apr 9;4(2):dlac037. doi: 10.1093/jacamr/dlac037. eCollection 2022 Apr. JAC Antimicrob Resist. 2022. PMID: 35415609 Free PMC article.
Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century.
Ngabonziza JCS, Rigouts L, Torrea G, Decroo T, Kamanzi E, Lempens P, Rucogoza A, Habimana YM, Laenen L, Niyigena BE, Uwizeye C, Ushizimpumu B, Mulders W, Ivan E, Tzfadia O, Muvunyi CM, Migambi P, Andre E, Mazarati JB, Affolabi D, Umubyeyi AN, Nsanzimana S, Portaels F, Gasana M, de Jong BC, Meehan CJ. Ngabonziza JCS, et al. Among authors: torrea g. J Clin Tuberc Other Mycobact Dis. 2022 Jan 24;27:100299. doi: 10.1016/j.jctube.2022.100299. eCollection 2022 May. J Clin Tuberc Other Mycobact Dis. 2022. PMID: 35146133 Free PMC article. Review.
Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda.
Ssengooba W, Komakech K, Namiiro S, Byabajungu H, Nalunjogi J, Katagira W, Kimuli I, Joloba ML, Adakun S, Nakiyingi L, Torrea G, Kirenga BJ. Ssengooba W, et al. Among authors: torrea g. J Clin Tuberc Other Mycobact Dis. 2021 Nov 6;25:100286. doi: 10.1016/j.jctube.2021.100286. eCollection 2021 Dec. J Clin Tuberc Other Mycobact Dis. 2021. PMID: 34816021 Free PMC article.
50 results